BPI-28592 / Betta Pharma - LARVOL DELTA

BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors. (PubMed, NPJ Precis Oncol) - P1 | "Clinically, BPI-28592 achieved a complete response in a patient with malignant melanoma carrying an AP3S2-NTRK3 fusion (Clinicaltrials. gov identifier: NCT05302843)."

Journal • Melanoma • Oncology • Solid Tumor • NTRK • NTRK2 • NTRK3

A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Betta Pharmaceuticals Co., Ltd.

New P1 trial • Oncology • Solid Tumor